SG11201704495VA - Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same - Google Patents

Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Info

Publication number: SG11201704495VA
Authority: SG; Singapore
Prior art keywords: hepe; compositions; treating; methods; same
Prior art date: 2014-12-02

Application number

SG11201704495VA

Inventor

Kevin Duffy

John Climax

Jonathan Rowe

Original Assignee

Afimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-02

Filing date

2015-12-02

Publication date

2017-06-29

2015-12-02 Application filed by Afimmune Ltd filed Critical Afimmune Ltd

2017-06-29 Publication of SG11201704495VA publication Critical patent/SG11201704495VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG11201704495VA 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same SG11201704495VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462086535P	2014-12-02	2014-12-02
PCT/US2015/063488 WO2016090030A1 (en)	2014-12-02	2015-12-02	Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Publications (1)

Publication Number	Publication Date
SG11201704495VA true SG11201704495VA (en)	2017-06-29

Family

ID=56092410

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201704495VA SG11201704495VA (en)	2014-12-02	2015-12-02	Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
SG10202010594WA SG10202010594WA (en)	2014-12-02	2015-12-02	Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10202010594WA SG10202010594WA (en)	2014-12-02	2015-12-02	Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Country Status (18)

Country	Link
US (1)	US10363235B2 (en)
EP (2)	EP3226873B1 (en)
JP (2)	JP6986445B2 (en)
KR (1)	KR20170102879A (en)
CN (2)	CN107206008A (en)
AU (2)	AU2015358512B2 (en)
BR (1)	BR112017011685A2 (en)
CA (1)	CA2968980A1 (en)
ES (1)	ES2900593T3 (en)
HK (1)	HK1245101A1 (en)
IL (2)	IL252431B (en)
MA (1)	MA41120A (en)
MX (2)	MX2017007000A (en)
PH (1)	PH12017501022A1 (en)
RU (2)	RU2721555C2 (en)
SG (2)	SG11201704495VA (en)
WO (1)	WO2016090030A1 (en)
ZA (2)	ZA201704463B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201301626D0 (en) *	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
CN109232278A (en)	2013-11-15	2019-01-18	Ds生物制药有限公司	The pharmaceutically acceptable salt of how unsaturated hydroxy fatty acid
WO2015106215A2 (en) *	2014-01-10	2015-07-16	Mehar Manku	Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
US20180008567A1 (en) *	2015-01-16	2018-01-11	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same
US10047033B2 (en)	2015-05-13	2018-08-14	Ds Biopharma Limited	Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
EP3389647B1 (en) *	2015-12-18	2023-04-05	Afimmune Limited	Compositions comprising 15-hepe
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6180671B1 (en) *	1998-03-10	2001-01-30	Beth Israel Deaconess Medical Center, Inc.	Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (en)	1998-12-25	2000-07-11	Nof Corp	Skin medicine composition for external use
WO2001049282A2 (en) *	2000-01-06	2001-07-12	Martek Biosciences Corporation	Therapeutic preparations of highly unsaturated fatty acids
EP1762557B1 (en)	2000-02-16	2011-04-06	The Brigham And Women's Hospital, Inc.	Aspirin-triggered lipid mediators
JP2005179211A (en)	2003-12-17	2005-07-07	Idemitsu Kosan Co Ltd	External preparation composition for skin
EP1711173A2 (en)	2003-12-31	2006-10-18	Igennus Limited	Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en)	2004-04-26	2005-11-03	Ltb4 Sweden Ab	In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
EP2607902B1 (en) *	2006-08-08	2017-10-04	Metabolon, Inc.	Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof
US8042070B2 (en) *	2007-10-23	2011-10-18	International Business Machines Corporation	Methods and system for analysis and management of parametric yield
GB0802116D0 (en) *	2008-02-05	2008-03-12	Natural Enviromental Res Counc	Treatment
PE20100156A1 (en) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	NAFLD TREATMENT
JPWO2009154230A1 (en)	2008-06-17	2011-12-01	持田製薬株式会社	Non-alcoholic steatohepatitis prevention / improvement / treatment drug
WO2010120880A1 (en) *	2009-04-14	2010-10-21	Vertex Pharmaceuticals Incorporated	Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
WO2012135032A2 (en) *	2011-03-25	2012-10-04	The Brigham And Women's Hospital, Inc.	Anti-inflammatory particles
US20120264824A1 (en) *	2011-04-15	2012-10-18	Mochida Pharmaceutical Co., Ltd.	Compositions and methods for treating non-alcoholic steatohepatitis
US8658787B2 (en) *	2011-09-16	2014-02-25	Galectin Therapeutics Inc.	Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
JP2014530841A (en)	2011-10-19	2014-11-20	ディグニティサイエンシスリミテッド	Pharmaceutical composition comprising DGLA and / or 15-HETRE and method of use thereof
US8293790B2 (en)	2011-10-19	2012-10-23	Dignity Sciences Limited	Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
KR20140113921A (en)	2011-11-29	2014-09-25	디그너티 사이언스 리미티드	Compositions comprising 20-carbon fatty acids and methods of making and using same
JP2015504870A (en) *	2011-12-16	2015-02-16	タリックスファーマシューティカルズリミテッド	Angiotensin for treating fibrosis
US20120264705A1 (en)	2012-01-26	2012-10-18	Dignity Sciences Limited	Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en)	2012-02-23	2013-10-10	Dignity Sciences Limited	Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
CA2873055C (en)	2012-05-10	2023-10-10	Solutex Na Llc	Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) *	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
TWI689489B (en) *	2013-03-15	2020-04-01	英商邊緣生物科技有限公司	Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
EP3389647B1 (en)	2015-12-18	2023-04-05	Afimmune Limited	Compositions comprising 15-hepe

2015
- 2015-12-01 MA MA041120A patent/MA41120A/en unknown
- 2015-12-02 CA CA2968980A patent/CA2968980A1/en not_active Abandoned
- 2015-12-02 AU AU2015358512A patent/AU2015358512B2/en not_active Ceased
- 2015-12-02 EP EP15865150.5A patent/EP3226873B1/en active Active
- 2015-12-02 ES ES15865150T patent/ES2900593T3/en active Active
- 2015-12-02 CN CN201580074543.0A patent/CN107206008A/en active Pending
- 2015-12-02 EP EP21200516.9A patent/EP3988101A1/en not_active Withdrawn
- 2015-12-02 CN CN202011279675.6A patent/CN112245419A/en active Pending
- 2015-12-02 BR BR112017011685-5A patent/BR112017011685A2/en not_active Application Discontinuation
- 2015-12-02 RU RU2017122758A patent/RU2721555C2/en active
- 2015-12-02 JP JP2017527848A patent/JP6986445B2/en active Active
- 2015-12-02 RU RU2020115523A patent/RU2020115523A/en unknown
- 2015-12-02 SG SG11201704495VA patent/SG11201704495VA/en unknown
- 2015-12-02 KR KR1020177018195A patent/KR20170102879A/en not_active Application Discontinuation
- 2015-12-02 MX MX2017007000A patent/MX2017007000A/en unknown
- 2015-12-02 SG SG10202010594WA patent/SG10202010594WA/en unknown
- 2015-12-02 WO PCT/US2015/063488 patent/WO2016090030A1/en active Application Filing
2016
- 2016-03-07 US US15/062,636 patent/US10363235B2/en active Active
2017
- 2017-05-22 IL IL252431A patent/IL252431B/en unknown
- 2017-05-29 MX MX2021005080A patent/MX2021005080A/en unknown
- 2017-06-01 PH PH12017501022A patent/PH12017501022A1/en unknown
- 2017-06-30 ZA ZA2017/04463A patent/ZA201704463B/en unknown
2018
- 2018-04-06 HK HK18104557.7A patent/HK1245101A1/en unknown
- 2018-06-29 ZA ZA2018/04380A patent/ZA201804380B/en unknown
2021
- 2021-05-18 AU AU2021203189A patent/AU2021203189A1/en not_active Abandoned
- 2021-11-10 IL IL287983A patent/IL287983A/en unknown
- 2021-11-29 JP JP2021192836A patent/JP2022031813A/en active Pending

Also Published As

Publication number	Publication date
IL252431A0 (en)	2017-07-31
HK1245101A1 (en)	2018-08-24
CA2968980A1 (en)	2016-06-09
AU2015358512B2 (en)	2021-02-18
CN107206008A (en)	2017-09-26
WO2016090030A1 (en)	2016-06-09
KR20170102879A (en)	2017-09-12
IL287983A (en)	2022-01-01
JP6986445B2 (en)	2021-12-22
RU2020115523A (en)	2021-01-27
CN112245419A (en)	2021-01-22
JP2017536380A (en)	2017-12-07
SG10202010594WA (en)	2020-12-30
MA41120A (en)	2017-10-10
US10363235B2 (en)	2019-07-30
ZA201704463B (en)	2018-11-28
RU2721555C2 (en)	2020-05-20
RU2017122758A3 (en)	2019-06-13
RU2017122758A (en)	2019-01-09
EP3988101A1 (en)	2022-04-27
EP3226873A1 (en)	2017-10-11
US20160184252A1 (en)	2016-06-30
AU2015358512A1 (en)	2017-07-20
AU2021203189A1 (en)	2021-06-10
JP2022031813A (en)	2022-02-22
MX2017007000A (en)	2017-12-07
ZA201804380B (en)	2021-03-31
PH12017501022B1 (en)	2017-11-27
ES2900593T3 (en)	2022-03-17
PH12017501022A1 (en)	2017-11-27
EP3226873A4 (en)	2018-08-08
EP3226873B1 (en)	2021-10-27
MX2021005080A (en)	2021-06-15
BR112017011685A2 (en)	2018-01-02
IL252431B (en)	2021-12-01

Publication	Publication Date	Title
HK1247238B (en)	2019-08-16	Engineered crispr-cas9 compositions and methods of use
HRP20192145T1 (en)	2020-05-15	Carrier-antibody compositions and methods of making and using the same
ZA202104969B (en)	2023-01-25	Compositions comprising 15-hepe and methods of using the same
ZA201701909B (en)	2018-05-30	Trichoderma compositions and methods of use
ZA201804380B (en)	2021-03-31	Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
PL3349743T3 (en)	2022-08-08	Methods and compositions of inhibiting dcn1-ubc12 interaction
HK1249515A1 (en)	2018-11-02	Methods and compositions for the prevention and treatment of hearing loss
SG11201702554QA (en)	2017-04-27	Compositions and methods for the treatment of multiple sclerosis
ZA201607878B (en)	2019-09-25	Compositions and methods of treating cardiac fibrosis with ifetroban
HK1247136A1 (en)	2018-09-21	Compositions comprising 15-hepe and methods of using the same
HK1252057A1 (en)	2019-05-10	Novel method of use and compositions
HK1250345A1 (en)	2018-12-14	Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
IL256843B (en)	2020-09-30	Cleaning compositions and methods of use therefor
HK1244692A1 (en)	2018-08-17	Methods of treating fibrosis
IL273850A (en)	2020-05-31	Compositions and methods for treatment of fibrosis
GB201511799D0 (en)	2015-08-19	Composition and methods of treatment
HK1243404A1 (en)	2018-07-13	Tryptamide compositions and methods of use
GB201621737D0 (en)	2017-02-01	Compositions and methods of treatment
GB201605127D0 (en)	2016-05-11	Composition and methods of treatment
IL261794A (en)	2018-10-31	Compositions and methods of their use
IL247645A0 (en)	2017-01-31	Compositions of selenoorganic compounds and methods of use thereof
EP3194446A4 (en)	2018-03-14	Compositions and methods for treating fibrosis
AU2015903210A0 (en)	2015-08-27	Compositions and methods of treatment
GB201521083D0 (en)	2016-01-13	Compositions for treatment and methods thereof
SG11201704282UA (en)	2017-06-29	Compositions and methods for the treatment of multiple sclerosis